The Role of Ubiquitination and Ubiquitin-like Modifications in the Oncogenic Fusion Protein BCR-ABL
International Journal of Molecular Sciences · 15.11.2026 · 27 (22) · 10231
DOI: 10.3390/ijms272210231 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.11.2026. Verfasst von Tara Shammas und 1 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UC San Diego Foundation.
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) is driven by the BCR-ABL fusion oncoprotein, a constitutively active tyrosine kinase whose inhibition by tyrosine kinase inhibitors (TKIs) transformed disease management. However, kinase-domain mutations, persistent leukemic stem cells (LSCs), and kinase-independent survival mechanisms still limit durable treatment-free remission. Increasing evidence indicates that BCR-ABL is regulated not only by kinase activity but also by post-translational modifications (PTMs) determining protein stability, turnover, interactions, and degradation. In this review, we examine how ubiquitination, SUMOylation, NEDDylation, phosphorylation, and acetylation-associated chaperone regulation control BCR-ABL proteostasis. Ubiquitin-dependent regulation involves opposing activities of E3 ligases and deubiquitinating enzymes, while TRIM28-mediated SUMOylation and RAPSYN-mediated NEDDylation stabilize BCR-ABL by limiting p62-dependent autophagic and c-CBL-mediated degradation, respectively. Crosstalk among these pathways suggests an integrated PTM network governs BCR-ABL fate rather than independent modifications. These mechanisms may impact persistent CML populations, though direct evidence linking specific PTMs to LSC maintenance remains limited. Therapeutically, manipulating PTM-dependent proteostasis via deubiquitinase inhibition, SUMO/NEDD8 modulation, chaperone disruption, and targeted protein degradation can complement conventional kinase inhibition. Notably, BCR-ABL-directed proteolysis-targeting chimeras (PROTACs) demonstrate the feasibility of eliminating the fusion protein rather than solely suppressing its catalytic activity. Ultimately, PTM-dependent proteostasis represents a critical regulatory dimension and therapeutic vulnerability in CML. Defining the spatial, temporal, and disease-specific PTM landscape of BCR-ABL is essential to determine if selective stability manipulation can overcome resistance and deepen therapeutic responses.
Förderung
- UC San Diego Foundation
Zitieren
APA
Shammas, T., & Donoghue, D. J. (2026). The Role of Ubiquitination and Ubiquitin-like Modifications in the Oncogenic Fusion Protein BCR-ABL. International Journal of Molecular Sciences, 27(22), 10231. https://doi.org/10.3390/ijms272210231
Vancouver
Shammas T, Donoghue DJ. The Role of Ubiquitination and Ubiquitin-like Modifications in the Oncogenic Fusion Protein BCR-ABL. International Journal of Molecular Sciences. 2026;27(22):10231. doi:10.3390/ijms272210231
BibTeX
@article{Shammas2026,
author = {Shammas, Tara and Donoghue, Daniel J.},
title = {The Role of Ubiquitination and Ubiquitin-like Modifications in the Oncogenic Fusion Protein BCR-ABL},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {22},
pages = {10231},
doi = {10.3390/ijms272210231}
}
EUVIMED